Articles

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

BIO recently published the July 2012 version of its quarterly therapeutic newsletters.  These six newsletters focus on the therapeutic areas of member companies and include updates from biotech stakeholders around Washington, including Congress, FDA, NIH, and patient organizations. 

The therapeutic areas covered by these newsletters are:

 

SBIR/STTR Reauthorization will restore eligibility to majority VC-backed emerging companies

The PMDxWorking Group endeavors to foster a positive public policy environment that maximizes the potential impact of the personalized medicine industry for the benefit of patients.

Bioscience economic development in a nation as large and diverse as the United States is as varied as the country itself.  A complex array of factors influence the allocation of resources and the nature of bioscience industry development.

For companies looking to partner in China, they must first realize the unique needs of this market.

“Farm Bill Energy Title Programs: Timeline of a Successful Policy Initiative” is a visual representation of the progress and results of Farm Bill energy programs.

“The Renewable Fuel Standard: Timeline of a Successful Policy” is a visual representation of the progress and results of the Renewable Fuel Standard (RFS).

Department: Federal Government Relations 

Reports to: Senior Director, Federal Government Relations 

Primary Purpose of the Position:  

This position will help manage BIO’s federal government relations lobbying and research efforts related to biopharmaceutical issues including Medicare/Medicaid reimbursement, the FDA drug approval process, and implementation of health care reform. 

 Responsibilities:

Using an input output “I-O” approach to estimating the economic impact of academic licensing, and summing over the 15 years of available data for academic U.S. AUTM Survey respondents, the total contribution of these academic licensors to gross industry output ranges from $199B to $836B, in 2005 $US Dollars; contributions to GDP range from $86B to $388B, in 2005 $US Dollars.

At a time when the global economy struggles to recover from a severe recession and uncertainty remains regarding future economic growth, bioscience industry development is generating significant attention both globally and at home.

This report examines the role played by IPRs in both upstream and downstream phases of the research, development and commercialization of biotechnology products and provides a review and analysis of the existing body of knowledge concerning the role of IPRs.

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have collaborated on a new report that builds upon the findings in BVGH’s previous analysis, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.

Successful multi-sector global health programs engage partners and policymakers early, communicate openly and frequently with relevant stakeholders, and empower and involve communities, according to a website relaunched this week, Case Studies for Global Health.

Commercial-scale advanced biofuel, renewable chemical, and biobased product biorefineries are in operation or under construction; pilot and demonstration projects continue to scale-up new technologies. 

For the fourth year in a row, BIO is working with bloggers and reporters from around the country (and Canada) to provide attendees with an inside look of what’s happening in Boston.

Farmers using improved seeds and biotech crop varieties continue to see significant economic and on-farm environmental benefits.

Gene Patents and the Myriad patent case reveal the confusion that often occurs when you mix science, law, politics, and emotion. This article provides a digest of a series of blog posts on Biotech-Now that address common myths in the gene patent debate.

The International Food Information Council (IFIC) survey, “Consumer Perceptions of Food Technology & Sustainability”, shows U.S. consumers overwhelmingly support current federal rules for labeling foods. 

Natural biological processes have been employed for food production for more than 8,000 years. Bread, cheese, yogurt, beer and wine, vinegar, and many other foods are produced through microbial fermentation or enzymatic activity.

Biotech allows us to meet the food production demands of a growing population in an economical way while lessening environmental impact.